Oisín Biotechnologies
Biotechnology company developing genetic medicines to combat sarcopenia and age-related diseases, with lead programs targeting skeletal muscle mass and strength without requiring exercise.
Website
https://www.oisinbio.comLocation
Seattle, Washington, USA
Founded
2016
Investors
1
Categories
biotech, longevity, aging, gene-therapy, sarcopenia
Notes
Oisín Biotechnologies is pioneering genetic medicines to combat sarcopenia (age-related muscle loss) and other age-related diseases. The company's lead candidate aims to increase skeletal muscle mass and strength without exercise, potentially benefiting older populations and those recovering from illnesses or surgeries.
Oisín's approach targets the fundamental biological mechanisms of aging, seeking to develop therapies that can address multiple age-related conditions simultaneously.
Team
- Gary Hudson - Co-Founder & Chief Executive Officer
- Matthew Scholz - Co-Founder
Additional Research Findings
- Founded in 2016 in Seattle, Washington
- Focus on genetic medicines for sarcopenia and aging
- Lead candidate targets skeletal muscle regeneration
- Funded $50,000 by VitaDAO for longevity research
- Part of the growing longevity/anti-aging therapeutics space
- Technology could benefit elderly and post-surgical recovery patients
- Uses gene therapy approaches to address age-related muscle loss
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| VitaDAO | Decentralized (Global) | dao | seed | 7 |